Teclistamab stands as a revolutionary cutting-edge anti-BCMA antibody drug compound, designated JNJ-64007957, demonstrating immense efficacy in the therapy of multiple myeloma. This innovative therapeutic operates by https://mediajx.com/story27654044/teclistamab-jnj-64007957-a-novel-anti-bcma-antibody-drug-conjugate-for-multiple-myeloma